Iranian
Biomedical Journal
Volume 30, Issue 2 And 3 (4-2026)
IBJ 2026, 30(2 And 3): 165-173 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bagheri A M, Forootanfar H, Dehghannoudeh G, Raeisi Estabragh M A, M. Banat I, Sokhandan H, et al . Antiviral Potential of Lipopeptide Biosurfactant Isolated from Acinetobacter junii B6. IBJ 2026; 30 (2 and 3) :165-173
URL: http://ibj.pasteur.ac.ir/article-1-5241-en.html
URL: http://ibj.pasteur.ac.ir/article-1-5241-en.html
Amir Mohammad Bagheri 
, Hamid Forootanfar , Gholamreza Dehghannoudeh , Mohammad Amin Raeisi Estabragh , Ibrahim M. Banat , Hosnieh Sokhandan , Hadiseh Shokouhi , Mandana Ohadi * , Parvaneh Mehrbod*
, Hamid Forootanfar , Gholamreza Dehghannoudeh , Mohammad Amin Raeisi Estabragh , Ibrahim M. Banat , Hosnieh Sokhandan , Hadiseh Shokouhi , Mandana Ohadi * , Parvaneh Mehrbod*
Abstract:
Background: Influenza A virus (IAV) is a global health concern, increasing the exploration of alternative therapeutics. Biosurfactants (BSs) are biodegradable, non-toxic biomolecules with favorable biological activities. Acinetobacter junii B6, known for utilizing crude oil as a carbon and energy source, produces BSs. This study evaluated the antiviral potential of the lipopeptide biosurfactant (LPB) against H1N1/A/PR8/34 infection.
Methods: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID50) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.
Results: The extracted LPB caused a 1 log2 reduction in pre- and post-exposure treatments, whereas amantadine and oseltamivir reduced viral titers by more than 1 log2. Cell protection was favorable in all combination treatments except for LPB co-treatment. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.
Conclusion: While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.
Methods: A. junii B6 LPB was extracted and characterized in our previous study. The 50% cytotoxic concentration and non-cytotoxic concentration (NCTC), defined as the concentration with no toxicity on cells, were determined by the MTT assay on MDCK cells. The NCTC was exposed to the cells in the presence of PR8 (100 TCID50) under simultaneous, pre- and post-exposure combination treatments for 1 h. After 48 h of incubation, the hemagglutination and MTT assays assessed viral propagation and cell protection, respectively. Amantadine and oseltamivir served as antiviral control drugs.
Results: The extracted LPB caused a 1 log2 reduction in pre- and post-exposure treatments, whereas amantadine and oseltamivir reduced viral titers by more than 1 log2. Cell protection was favorable in all combination treatments except for LPB co-treatment. LPB extract showed limited but notable anti-IAV activity, alongside cell protection.
Conclusion: While LPB is less potent than amantadine and oseltamivir, its non-toxic and environmentally friendly nature warrants further study. As surfactants act on the lipid envelope, viral proteins, and nucleocapsid proteins, LPB could be potentially used as an adjuvant with other antiviral agents to control the prevalence of viral diseases and improve therapeutic outcomes.
Type of Study: Full Length/Original Article |
Subject:
Pharmaceutical Biotechnology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
IBJ is a member of Committee on Publication Ethics (COPE)
and follows its guidelines |
The articles of this journal are licensed under
a Creative Commons Attribution-NonDerivatives 4.0 International License. .png) |
 IBJ is owned and published by Pasteur Institute of Iran |